Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.


TSX:TH - Post by User

Comment by SPCEO1on Mar 30, 2023 2:33pm
102 Views
Post# 35369893

RE:RE:RE:RE:Where's the news on TH1902?

RE:RE:RE:RE:Where's the news on TH1902? We will have to wait until the proxy statement comes out to know if there were salary reductions or bonuses not paid. Hopefully, that is what we will see and the big, cheap option grants helped offset the sting of that.

My sense is the management team THTX has in place is for the most part actually pretty good and would be hard to replace with equivalent talent at this point. The situation is also one where the failure on TH-1902 is not final, so their expertise surrounding that is still valuable as the next data dump  on TH-1902, likely early next eyar, could be good and could set the company on a very positive path. So, I can see why the board would want to offer them a large amount of cheap options to see if they can push TH-1902 past the finish line.
realitycheck4u wrote: Yet not from dumping millions of options into their hands with dismal share price performance, and prior to the lockout, virtually zero shares purchased. Where are the salary cuts?

SPCEO1 wrote: From what  I understand, they are still locked out from any trading. But after getting all those cheap options, it would really be a positive development if they added to their stakes by buying more in the open market. I don't expect to see that, however.
Joemare wrote: Have insiders, the executives of this mega pharma company, started to buy shares.........






<< Previous
Bullboard Posts
Next >>